title: Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population.
abstract: Recent studies have suggested that vitamin D is an important determinant of prostate cancer risk and inherited polymorphisms in the 3'-untranslated region (3'UTR) of the vitamin D receptor (VDR) gene are associated with the risk and progression of prostate cancer. This study was conducted to explore the association of VDR gene polymorphisms with prostate cancer risk in Japanese men who are considered to be much less influenced by environmental risk factors for prostate cancer. We studied 222 prostate cancer patients, 209 benign prostatic hyperplasia (BPH) patients, 128 male controls who were over 60 years old and without any evidence of prostate cancer or BPH, and 198 female controls. A PCR-RFLP method was used to determine three VDR gene polymorphisms in the 3'UTR characterized by restriction enzymes BsmI, ApaI and TaqI. In the BsmI polymorphism, heterozygosity or homozygosity for the absence of the BsmI restriction site was associated with one-third the risk of prostate cancer (P < 0.0001; odds ratio, 3.31; 95% confidence interval, 2.05-5.32) and with one-half the risk of BPH (P < 0.005; odds ratio, 2.07; 95% confidence interval, 1.33-3.22) compared with the male controls. The TaqI and ApaI polymorphisms did not show any significant association with either prostate cancer or BPH. The results indicate that the BsmI polymorphism in the VDR gene plays a significant role in protection against prostate cancer and BPH. Because of the racial difference in the strength of the linkage disequilibrium between the three polymorphisms, additional studies are required to apply the present results to other racial-ethnic groups.
authors.affiliation: Department of Urology, Akita University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Habuchi
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: R
authors.initials: R
authors.lastname: Sasaki
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: S
authors.initials: S
authors.lastname: Satoh
authors.forename: T
authors.initials: T
authors.lastname: Akao
authors.forename: N
authors.initials: N
authors.lastname: Tsuchiya
authors.forename: N
authors.initials: N
authors.lastname: Shimoda
authors.forename: Y
authors.initials: Y
authors.lastname: Wada
authors.forename: A
authors.initials: A
authors.lastname: Koizumi
authors.forename: J
authors.initials: J
authors.lastname: Chihara
authors.forename: O
authors.initials: O
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Kato
mesh_terms: D020413:3' Untranslated Regions / Q000235:genetics; D000368:Aged; D016001:Confidence Intervals; D015252:Deoxyribonucleases, Type II Site-Specific; D005260:Female; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D007564:Japan; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D011470:Prostatic Hyperplasia / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics*; D018167:Receptors, Calcitriol / Q000235:genetics*; D012307:Risk Factors
chemical_list: D020413:3' Untranslated Regions; D018167:Receptors, Calcitriol; C053864:endodeoxyribonuclease BsmI; D015252:Deoxyribonucleases, Type II Site-Specific; C038485:GGGCCC-specific type II deoxyribonucleases; C027046:TCGA-specific type II deoxyribonucleases